



Date: 28th January, 2015

Granules India Limited

Regd. Off. :

2nd Floor, 3rd Block, My Home Hub, Madhapur, Hyderabad - 500 081, INDIA

Ph : +91-40-30660000, 66760000 Fax : +91-40-23115145

E-mail : mail@granulesindia.com URL : www.granulesindia.com

CIN : L24110TG1901PLC012471

To
The Manager
Listing Department
National Stock Exchange of India Limited
'Exchange Plaza', C-1, Block G
Bandra-Kurla Complex, Bandra (E)
Mumbai – 400 051

**Sub: Outcome of 161st Board meeting dated 28th January, 2015.
Scrip Code: GRANULES.**

Dear Sir,

The Board of Directors at their meeting has approved the following:-

1. The Un-Audited financial results (Standalone & Consolidated) for the third quarter ended 31st December, 2014 along with the limited review report thereon;
2. Subject to approval of Shareholders, to split / sub-divide the face value of the Company's equity shares from Rs. 10/- each to Rs. 1/- each;
3. Subject to approval of Shareholders, raising of funds by the Company for an amount of Rs. 250 crores with applicable green shoe option through issue of securities through a Qualified Institutions Placement ("QIP") to Qualified Institutional Buyers ("QIB") as per the SEBI (ICDR) Regulations;
4. Constitution of Qualified Institutions Placement Committee;
5. To hold a General Meeting of the members of the Company on 27th February 2015.


Please also find the enclosed Un-Audited financial results for the third quarter ended 31st December, 2014 and press release.

Request you to take the above information on record.
Thanking You.

Yours faithfully,

For GRANULES INDIA LIMITED

G. Chaitanya.
CHAITANYA TUMMALA
(COMPANY SECRETARY &
COMPLIANCE OFFICER)



Encl: As above



Press Release

Granules India's Revenue increases 13% to Rs. 320 Cr.; Net Profit rises 8% to Rs. 24 Cr.

Hyderabad, January 28, 2015: Granules India Ltd., a fast growing pharmaceutical manufacturing company, announced financial results for its Third Quarter ended 31st December, 2014.

Consolidated Q3FY15 Financial Highlights

- Net Revenue: Rs. 319.7 Cr., an increase of 13% compared to Rs. 284.1 Cr. in Q3FY14
- EBITDA: Rs. 55.3 Cr., an increase of 21% compared to Rs. 45.5 Cr. in Q3FY14
- Net Profit: Rs. 23.6 Cr., an increase of 8% compared to Rs. 21.8 Cr. in Q3FY14

The Company's focus on operational efficiency helped improved EBITDA margin by 127 basis points compared to the corresponding quarter in the previous financial year. Finished Dosages continue to be the largest contributor to the business and constituted 42% of standalone sales. Sales to the regulated markets increased to 69% against 63% in Q3FY14

The Company's standalone sales during the quarter were Rs. 319.5 Cr. an increase of 22% from same period last financial year. The EBITDA was Rs. 56.9 Cr. with a margin improvement of 51 basis points to 17.8% while PAT improved to Rs. 24.4 Cr.

During the quarter, the order of the Honourable High Court of Judicature at Hyderabad for the State of Telangana & Andhra Pradesh sanctioning the Scheme of Amalgamation for Auctus Pharma Ltd. with Granules India Ltd. became effective. Due to merger of Auctus Pharma Ltd. (APL) with Granules India Ltd. current quarter and year till date up to Dec-2014 stand-alone numbers are not comparable with the previous quarter and the corresponding previous year periods figures.

The Board of Directors today approved fund raising by issue of equity shares to Qualified Institutional Buyers ("QIB") to the extent of Rs.250 Cr with applicable green shoe option through a Qualified Institutions Placement ("QIP") as per the SEBI (ICDR) Regulations. The Board of Directors also approved today split/sub-division of the face value of the Company's equity shares from Rs. 10 each to Rs. 1 each. Both the proposals are subject to the approval of the Shareholders.

"This is a year of consolidation for us and we are encouraged to see growth in Revenue and Profit along with improved operational margins compare to the same quarter previous year in the midst of business integration. We remain focused on strengthening our existing businesses and developing a product basket through capitalising the strategic efforts we have initiated in the past by way of Auctus acquisition and establishing indigenous Research Centre. Our vertical integration continues to differentiate us and we will build on our strength by commercializing additional PFI capacity this quarter. We also continue to expand and strengthen our global footprint by creating a deeper relationship with our customers." said Krishna Prasad, Chairman & Managing Director of Granules India.



About Granules India Ltd.

(BSE: 532482, NSE: GRANULES)

Granules is a fast growing pharmaceutical manufacturing company with world class facilities and is committed to manufacturing excellence, quality and customer service. The Company produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) for quality conscious customers in the regulated and semi-regulated markets. Granules support customers with unique value, extensive product range, proactive solutions and a global network of associates. The Company's global presence extends to over 300 customers in 60 countries through offices in India, U.S., U.K., China and Colombia. Granules offer all three components of the pharmaceutical value chain which gives the customers flexibility and choice.

Granules has the largest PFI facility in the world with an industry leading 6 ton batch size. The Company has its own ANDAs and dossiers which enable customers to quickly enter a market instead of filing their own applications. Granules has a highly skilled regulatory affairs department that can offer customers support and can help them navigate through regulatory issues.

Granules has strengthened its advantages through its Operational Excellence (OE) department which looks at every step of the manufacturing process in order to gain efficiencies and has also implemented systems that have standardized quality and reduced variation. The Company's OE program is regularly cited by MNCs as a "best in class" program and is the comparative advantage that lets Granules provide world-class quality products at a lower cost than its competitors. The adoption of the OE philosophy by Granules has earned it several recognitions including The Economic Times Manufacturing Excellence Awards 2011.

Caution Statement:

Certain statements made above may be "forward looking statements" within the meaning of applicable laws and regulations.

Contacts:

Gayatri Ganesh
Genesis Burson-Marsteller
+91 9703700884
gayatri.ganesh@bm.com

Appendix